Suggested remit: To appraise the clinical and cost effectiveness of abrocitinib within its marketing authorisation for moderate to severe atopic dermatitis in people aged 12 and over.
We are continuing to face significant capacity challenges and will be delaying the development of abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022.
 
Status Schedule affected by COVID-19
Process STA 2018
ID number 3768

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Consultees

Companies sponsors Pfizer (abrocitinib)
Others Department of Health and Social Care
  NHS England
  NHS Barking & Dagenham CCG
  NHS Walsall CCG
  Welsh Government
Patient carer groups Action for Sick Children
  Allergy UK
  British Skin Foundation
  Changing Faces
  Contact
  Eczema Outreach Support
  Let’s Face It
  National Eczema Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of Paediatric Emergency Medicines
  British Association for Immediate Care
  British Association of Dermatologists
  British Dermatological Nursing Group
  British Society for Cutaneous Allergy
  British Trauma Society
  Neonatal and Paediatric Pharmacists Group
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Paediatrics & Child Health
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Primary Care Dermatology Society
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (azathioprine, methotrexate, mycophenolate mofetil)
  ADVANZ Pharma (methotrexate)
  Aspen (azathioprine)
  Cipla (methotrexate)
  Dexcel Pharma (ciclosporin)
  Eli Lilly (baricitinib)
  Ennogen Pharma (alitretinoin, azathioprine)
  Hospira UK (methotrexate)
  medac GmbH (methotrexate)
  Morningside Healthcare (methotrexate)
  Mylan (azathioprine, ciclosporin)
  Nordic Pharma (methotrexate)
  Novartis Pharmaceuticals (ciclosporin)
  Orion Pharma (methotrexate)
  Pfizer (methotrexate)
  Roche (mycophenolate mofetil)
  Rosemont Pharmaceuticals (methotrexate)
  Sandoz (methotrexate)
  Sanofi Genzyme (dupilumab)
  Santen UK (ciclosporin)
  Stiefel (alitretinoin)
  Teva Pharma (mycophenolate mofetil)
  Therakind (methotrexate)
  Tillomed Laboratories (azathioprine, mycophenolate mofetil)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Epidermo-Epidemiology Society
  Centre of Evidence-based Dermatology, University of Nottingham
  Cochrane Skin Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Skin Treatment & Research Trust

Timeline

Key events during the development of the guidance:

Date Update
05 August 2021 Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960].
21 July 2021 We are continuing to face significant capacity challenges and will be delaying the development of abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022.
21 July 2021 Schedule affected by COVID-19. We are continuing to face significant capacity challenges and will be delaying the development of abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022.
15 March 2021 Invitation to participate
25 November 2020 - 23 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance